Braidwell

One Harbor Point, 2200 Atlantic Street
Stamford, CT 6902

Website: braidwell.com

Firm Size

• Assets Under Management (AUM):$7.5 Billion
• Number of Funds:8
• Employees:38
• Firm Type:Hedge Fund

Description

Braidwell LP is a company based in Stamford, Connecticut. They specialize in providing various services related to hair braiding. With their team of skilled and experienced professionals, they offer a range of braiding styles for men, women, and children. Braidwell LP takes pride in their commitment to delivering high-quality services, ensuring customer satisfaction. They offer consultations to understand their clients' needs and preferences, guaranteeing personalized and tailored results. Whether it's intricate cornrows, box braids, twist styles, or other innovative braiding techniques, Braidwell LP aims to deliver exceptional craftsmanship. In addition to their braiding services, Braidwell LP also provides hair care and maintenance tips. Their knowledgeable team advises clients on proper haircare routines, products, and practices to maintain the longevity and health of braided hairstyles. Conveniently located in Stamford, Braidwell LP offers a welcoming and comfortable environment for customers to have their hair braided. They strive to create a positive experience, ensuring a relaxed atmosphere throughout the appointment. Overall, Braidwell LP is a reputable company in Stamford, CT, known for their expertise in hair braiding and exceptional customer service. They aim to enhance their clients' appearance and confidence through their skillful craftsmanship and dedication to delivering top-notch services.

Latest News

Powered by

Dec 07, 2023: Spyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Access Biotechnology, Venrock Healthcare Capital Partners, Perceptive Advisors, RTW Investments, LP, Braidwell LP, Fairmount, Cormorant Asset Management, Polar Capital, Boxer Capital, Deep Track Capital, Great Point Partners LLC, Affinity Asset Advisors, Commodore Capital, Woodline Partners LP, a leading biotechnology investor associated with one of the largest alternative asset managers, and a large investment management firm.